Akebia Therapeutics Inc. buy BTIG Research
Start price
29.10.25
/
50%
€1.93
Target price
29.10.26
€4.29
Performance (%)
-44.50%
Price
08:56
?
Summary
This prediction is currently active. The BUY prediction by BTIG_Research for Akebia Therapeutics Inc. is performing very badly with a performance of -44.50%. This prediction currently runs until 29.10.26. The prediction end date can be changed by BTIG_Research at any time. BTIG_Research has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Akebia Therapeutics Inc. | 0.686% | 0.686% |
| iShares Core DAX® | -3,81 % | -1,47 % |
| iShares Nasdaq 100 | 0,49 % | 2,21 % |
| iShares Nikkei 225® | -4,42 % | 4,97 % |
| iShares S&P 500 | 0,25 % | 1,23 % |
Comments by BTIG_Research for this prediction
In the thread Akebia Therapeutics Inc. diskutieren
Akebia Therapeutics (NASDAQ:AKBA) had its price target lowered by analysts at BTIG Research from $10.00 to $5.00. They now have a "buy" rating on the stock.
Ratings data for AKBA provided by MarketBeat
Stopped prediction by BTIG_Research for Akebia Therapeutics Inc.
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.08
25.02.26
25.02.26
€3.39
25.02.27
25.02.27
-0.56%
08:56
08:56
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.27
02.12.25
02.12.25
€4.31
02.12.26
02.12.26
-16.01%
08:56
08:56
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€0.92
29.11.23
29.11.23
€3.64
29.11.24
29.11.24
122.78%
30.11.24
30.11.24